# Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma

> **NCT01916187** · PHASE1 · WITHDRAWN · sponsor: **NCIC Clinical Trials Group**

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Imetelstat

## Key facts

- **NCT ID:** NCT01916187
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-07-30
- **Primary completion:** 2013-11-22
- **Final completion:** 2014-01-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** drug company withdrew support following re-examination of benefit-risk assessment for the investigational use of imetelstat in this population
- **Last updated:** 2020-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01916187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01916187, "Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01916187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*